The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
What is the relationship between the SF3B1 splicing mutation and therapy-related MDS?
Featured:
Virginia VolpeDuring the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub spoke to Virginia Volpe, Moffitt Cancer Center, Tampa, US. We asked: What is the relationship between the SF3B1 splicing mutation and therapy-related MDS?
What is the relationship between the SF3B1 splicing mutation and therapy-related MDS?
Here, Virginia Volpe discusses the similarities and differences in characteristics between patients with SF3B1 mutations and de novo MDS vs treatment-related MDS. Additionally, she compares patients harboring SF3B1 mutations vs those with wild type SF3B1 in these disease settings.